140 related articles for article (PubMed ID: 35502409)
1. Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?
Hagag RY; Selim AF; Darrag OM; Zied H; Aboelnasr MS
Diabetes Metab Syndr Obes; 2022; 15():1261-1268. PubMed ID: 35502409
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
Kurokawa K; Ohki T; Kato J; Fukumura Y; Imai M; Shibata C; Arai J; Kondo M; Takagi K; Kojima K; Seki M; Mori M; Toda N; Tagawa K
J Med Case Rep; 2020 May; 14(1):62. PubMed ID: 32456712
[TBL] [Abstract][Full Text] [Related]
3. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
[TBL] [Abstract][Full Text] [Related]
6. High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
El-Nahaas SM; Fouad R; Elsharkawy A; Khairy M; Elhossary W; Anwar I; Abdellatif Z; Maher RM; Bekheet N; Esmat G
Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1194-1199. PubMed ID: 30096091
[TBL] [Abstract][Full Text] [Related]
7. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
8. Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: A multicenter study.
Takahashi H; Nakahara T; Kogiso T; Imajo K; Kessoku T; Kawaguchi T; Ide T; Kawanaka M; Hyogo H; Fujii H; Ono M; Kamada Y; Sumida Y; Anzai K; Shimizu M; Torimura T; Nakajima A; Tokushige K; Chayama K; Eguchi Y;
JGH Open; 2021 Feb; 5(2):228-234. PubMed ID: 33553660
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.
Sun HY; Cheng CY; Lin CY; Yang CJ; Lee NY; Liou BH; Tang HJ; Liu YM; Lee CY; Chen TC; Huang YC; Lee YT; Tsai MJ; Lu PL; Tsai HC; Wang NC; Hung TC; Cheng SH; Hung CC
World J Gastroenterol; 2022 Mar; 28(11):1172-1183. PubMed ID: 35431505
[TBL] [Abstract][Full Text] [Related]
10. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
[TBL] [Abstract][Full Text] [Related]
11. Anti-rod and ring antibodies in patients with chronic hepatitis C using direct-acting antivirals.
da Silva Sacerdote AB; Filgueira NA; de Barros Barreto S; Batista AD; Lopes EP
Immunol Res; 2020 Jun; 68(3):111-117. PubMed ID: 32537670
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir Based Regimen in Management of Hepatitis C for Patients With End Stage Renal Disease on Hemodialysis: A Single Center Experience from India.
Gupta A; Arora P; Jain P
J Clin Exp Hepatol; 2018 Jun; 8(2):116-120. PubMed ID: 29892172
[TBL] [Abstract][Full Text] [Related]
13. Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment.
Tang LS; Masur J; Sims Z; Nelson A; Osinusi A; Kohli A; Kattakuzhy S; Polis M; Kottilil S
World J Hepatol; 2016 Nov; 8(31):1318-1326. PubMed ID: 27872683
[TBL] [Abstract][Full Text] [Related]
14. Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
Hanif FM; Mandhwani R; Lail G; Luck NH; Aziz T
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):198-201. PubMed ID: 30777554
[TBL] [Abstract][Full Text] [Related]
15. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
[TBL] [Abstract][Full Text] [Related]
16. Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
Dhiman RK; Grover GS; Premkumar M; Taneja S; Duseja A; Arora S; Rathi S; Satsangi S; Roy A;
J Hepatol; 2019 Dec; 71(6):1076-1085. PubMed ID: 31325468
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.
Rinaldi L; Perrella A; Guarino M; De Luca M; Piai G; Coppola N; Pafundi PC; Ciardiello F; Fasano M; Martinelli E; Valente G; Nevola R; Monari C; Miglioresi L; Guerrera B; Berretta M; Sasso FC; Morisco F; Izzi A; Adinolfi LE
J Transl Med; 2019 Aug; 17(1):292. PubMed ID: 31462268
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection.
Gupta S; Rout G; Patel AH; Mahanta M; Kalra N; Sahu P; Sethia R; Agarwal A; Ranjan G; Kedia S; Acharya SK; Nayak B; Shalimar
J Viral Hepat; 2018 Jul; 25(7):771-778. PubMed ID: 29377464
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients.
Younas S; Mukhtar H; Gohar UF; Alsrhani A; Alzahrani B; Junaid K; Qamar MU; Ejaz H
J Infect Dev Ctries; 2021 Oct; 15(10):1489-1496. PubMed ID: 34780372
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
Mohamed MS; Hanafy AS; Bassiony MAA; Hussein S
Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1368-1372. PubMed ID: 28953002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
